Overview

Comparative Effects of Milk Thistle Extract With Vitamin-E in Hemodialysis Patients

Status:
Completed
Trial end date:
2010-05-01
Target enrollment:
0
Participant gender:
All
Summary
For end-stage renal disease (ESRD) patients, cardiovascular disease remains the single most common cause of excess morbidity and mortality. Among the examined nontraditional risk factors, an increase in oxidative stress as well as inflammation are postulated to contribute to excessive cardiovascular risk in this population. Flavonoids are naturally occurring substances that possess various pharmacological actions and therapeutic applications. Some due to their phenolic structures have antioxidant effect and inhibit free radical-mediated processes, as well as anti-inflammatory effects. Silymarin,a mixture of three isomeric flavonolignans, is isolated from milk thistle (Silybum marianum) seeds, and is proven to have anti-oxidant, anti-inflammatory, cell regenerating, and antifibrotic action. In this study, the effect of silymarin on oxidative stress and inflammation (2 major risk factors for cardiovascular morbidity and mortality in hemodialysis patients)is evaluated, and compared to vit E, a well known antioxidant.
Phase:
Phase 2
Accepts Healthy Volunteers?
No
Details
Lead Sponsor:
Shiraz University of Medical Sciences
Treatments:
alpha-Tocopherol
Tocopherols
Vitamin E
Criteria
Inclusion Criteria:

- All hemodialysis patients age 18-60

- On hemodialysis for over 3 months, 3 times a week, and for 4 hours each time

- Signed informed consent

Exclusion Criteria:

- Heart Failure NYHA Class III or IV

- Recent MI (within 1 year)

- Use of anti-oxidant supplements: N-acetyl-cystein, Omega 3, Vit C, Vit E, green tea,
soy extracts, pomegranate extract, grape extract..

- Hepatitis B or C

- Active Infection

- Psychiatric illness

- Active malignancy